Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM)

1. ATNM is facing a class action over misleading statements. 2. Allegations include doubts about FDA approval of Iomab-B. 3. Class period spans from October 31, 2022, to August 2, 2024. 4. Shareholders can register for updates and potential recovery. 5. The deadline for lead plaintiff appointment is May 27, 2025.

Legal

95

4m saved

Insight

Article

FAQ

Why Very Bearish?

Allegations of misleading statements regarding FDA approval could significantly damage shareholder confidence. Historical instances show that such lawsuits can lead to major sell-offs, as seen with other biotech firms facing similar issues.

How important is it?

The class action concerns misrepresentation that could lead to significant stock price drops, impacting many investors. This level of scrutiny from legal actions makes it highly relevant for ATNM's market perception.

Why Short Term?

The immediate market reaction will likely be negative as more investors become aware of the lawsuit. Short-term declines in stock price are common in similar situations.

Related Companies

IBB XBI MDGL CRMD ADMA

NOTICE TO SHAREHOLDERS OF ACTINIUM PHARMACEUTICALS, INC.

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).

Important Information for Shareholders

Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Click here to contact us

CLASS PERIOD

October 31, 2022 to August 2, 2024

ALLEGATIONS

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:

(1) the Company's data from the Phase 3 Sierra trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's targeted radiotherapy, Iomab-B BLA;
(2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA;
(3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved;
(4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE

May 27, 2025. Shareholders should not delay in registering for this class action. Register your information here:

Click here to register

NEXT STEPS FOR SHAREHOLDERS

Once you register as a shareholder who purchased shares of ATNM during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 27, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm